Investors
Why Invest in CRDG Member Companies?
Investing in CRDG member companies offers access to early-stage innovations in biotech, pharmaceuticals, and therapeutics. We help connect investors with companies that align with their goals.
Research and Innovation
Our member companies focus on cutting-edge research in cannabinoid medicine.
Market Growth
The cannabinoid medicine market is expanding, driven by increasing demand for new treatments.
Expert Support
Our co-chairs, George Freeman MP and Professor Trevor Jones CBE FMed Sci, provide CRDG with valuable advice on engaging with key investors, academia and industry leaders. Their expertise and connections offer a solid foundation for growth in the cannabinoid medicine sector.
Success Stories
The success of GW Pharmaceuticals, acquired for $7.2 billion by Jazz Pharmaceuticals, underscores the growth potential in this field. In the first year after the acquisition, Jazz reported over $658 million in sales from Epidiolex, GW’s flagship cannabinoid-based therapy.
Several CRDG member companies have already made significant progress, from securing funding to advancing clinical trials. Their success highlights the potential for growth and impact in this sector.
CRDG Press Coverage
September 2024
How the UK could become a leader in cannabinoid research – Drug Discovery World
July 2024
UK life sciences can lead the way in cannabinoid R&D, says report – Drug Discovery World
UK life sciences can lead global cannabinoid R&D – European Pharmaceutical Manufacturer
June 2024
New task force aims to establish UK as ‘global leader’ in cannabinoid science – Cannabis Health
Get in Touch
To learn more about investment opportunities in cannabinoid medicine R&D, contact Steve Moore at steve@crdg.uk or call +44 7870 515025.
Investor Newsletter
Sign up for CRDG investor updates to be notified of our investor events and other news.